POINT RICHMOND, Calif., May 5, 2011/PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, May 16, 2011 at 4:30 p.m. Eastern Time to discuss its first quarter 2011 financial results. The conference call will follow the release of the Transcept first quarter 2011 financial results after the close of market that day.
(Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO)
Conference Call Information | ||
Date: Monday, May 16, 2011 | ||
Time: 4:30 p.m. EDT | ||
Dial-in (U.S.): 877-638-4558 | ||
Dial-in (International): 914-495-8537 | ||
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through July 31, 2011.
A telephone replay of the conference call will be available shortly after the conclusion of the call through May 20, 2011. The replay telephone number is 800-642-1687 (U.S.) or 706-645-9291 (International), replay passcode: 62344930.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet). Transcept has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) that seeks approval of Intermezzo® as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The FDA has assigned a date of July 14, 2011 for its completion of the Intermezzo® NDA review. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.
In March 2011, Transcept initiated a Phase 2 study of TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy. For further information, please visit the Transcept website at: www.transcept.com.
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
gmann@transcept.com
SOURCE Transcept Pharmaceuticals, Inc.
